Jesus Gomez-Catalan

Dr. Jesus Gomez-Catalan

Universitat de Barcelona, Barcelona, Catalonia, Spain

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
GPGemma Perelló
Gemma Perelló
JGJesus Gomez-Catalan
Jesus Gomez-Catalan
VCVictoria Castell
Victoria Castell
JLJuan M. Llobet
Juan M. Llobet
Jose L DomingoJose L Domingo
Jose L Domingo

1 February 2013 in Toxicology in Vitro
Verified
Journal Article
Closed access
Elisabet TeixidoElisabet Teixido
Elisabet Teixido
EPEster Pique
Ester Pique
JGJesus Gomez-Catalan
Jesus Gomez-Catalan
JLJ.M. Llobet
J.M. Llobet

1 August 1997 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
JTJ To-Figueras
J To-Figueras
MGM Gené
M Gené
JGJesus Gomez-Catalan
Jesus Gomez-Catalan
MGM C Galán
M C Galán
MFM Fuentes
M Fuentes
JCJ Corbella
J Corbella
Several polymorphic genes including those encoding for glutathione S-transferases (GST) have been reported to be involved in modifying lung cancer risk in smokers. The gene GSTM1 is frequently deleted in humans and a possible association between the null genotype and lung cancer risk is controversial. Another polymorphic gene of the same supergene family, GSTT1, is also involved in the detoxification of some environmental carcinogens. Both genes were genotyped in (a) a group of lung cancer patients (n = 160); (b) a group of healthy smokers (n = 120); (c) a group of blood donors from the general population (n = 192). All patients and controls were Northwestern Mediterranean Caucasians. The results show that the GSTM1 null genotype (GSTM1*0/GSTM1*0) was slightly over represented in the lung cancer patients (frequency of 58%; OR: 1.40, 95% CI: 0.74-2.61, referred to healthy smokers). The histological type most clearly modified was small cell carcinoma (frequency of 62.2%, OR: 1.91, CI: 0.78-4.69). The subdivision of the patients with one or two copies of the GSTM1 gene according to a GSTM1*A, GSTM1*B or GSTM1*A/B genotype (frequencies of 28.2%, 11.2%, 2.5% respectively) revealed no significant differences between the cases and both control groups. The frequency of the deleted GSTT1 genotype among the lung cancer patients (24%) was not significantly increased (OR: 1.08, CI: 0.57-2.05, referred to healthy smokers). The results showed that 14.4% of the patients presented homozygous deletion of both GSTT1 and GSTM1 (12.5% among healthy smokers) suggesting no potentiation between null genotypes for lung cancer risk.

1 August 2015 in Food Chemistry
Verified
Journal Article
Closed access
Anna Vallverdu-QueraltAnna Vallverdu-Queralt
Anna Vallverdu-Queralt
NBNuria Boix
Nuria Boix
EPEster Pique
Ester Pique
JGJesus Gomez-Catalan
Jesus Gomez-Catalan
AMAlexander Medina-Remon
Alexander Medina-Remon
Rosa Lamuela-RaventosRosa Lamuela-Raventos
Rosa Lamuela-Raventos

31 May 2000 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AJAna I. Jiménez
Ana I. Jiménez
CCCarlos Cativiela
Carlos Cativiela
JGJesus Gomez-Catalan
Jesus Gomez-Catalan
JPJuan Jesus Perez
Juan Jesus Perez
AAAndré Aubry
André Aubry
MMMichel Marraud
Michel Marraud